Momentum and Risks You Must See Before Investing in Biotech Stocks

Summary

After a 10% KOSDAQ drop, CEO Lee Kwon-hee explains the rebound, highlights SK Hynix's ADR listing as a major positive, and discusses the biotech sector surge. He remains bullish on the uptrend but urges caution on biotech entries until key resistance levels break.

• KOSDAQ fell 10% on rebalancing but rebounded 3.3%, with Lee viewing the uptrend as alive.
• SK Hynix's 45 trillion won ADR listing on Nasdaq is a positive catalyst, potentially boosting valuation and index inclusion.
• Micron earnings will be a key short-term driver for semiconductor stocks.
• Korean biotech stocks rallied sharply, possibly catching up with US biotech index highs.
• Lee urges waiting for key resistance levels to break before buying Samsung Biologics and LigaChem.
• Samsung Electronics appears undervalued relative to SK Hynix, suggesting upside potential.
• Volatility likely to persist until end of June due to half-year rebalancing.
• FX worries are overblown; the won is expected to strengthen by year-end.